

Form PTO-1449 (R v. 8-88)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. C-3527/1/US	Serial No. 10/072,668
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Alice C. Martino et al.	AUG 14 2002
		Filing Date February 7, 2002	Group No. Unknown

RECEIVED  
U.S. PATENT AND TRADEMARK OFFICE  
AUG 12 2002

## U.S. PATENT DOCUMENTS

Examiner Initial*	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	3,885,026	May 20, 1975	Heinemann et al.	424	14	
	3,901,248	Aug 26, 1975	Lichtneckert et al.	131	2	
	4,134,943	Jan 16, 1979	Knitsch et al.	264	28	
	4,305,502	Dec 15, 1981	Gregory et al.	206	532	
	4,371,516	Feb 01, 1983	Gregory et al.	424	22	
	4,414,198	Nov 08, 1983	Michaelson	424	44	
	4,847,090	Jul 11, 1989	Della Posta et al.	424	440	
	4,855,326	Aug 08, 1989	Fuisz	514	777	
	4,946,684	Aug 07, 1990	Blank et al.	424	441	
	5,073,374	Dec 17, 1991	McCarty	424	435	
	5,082,667	Jan 21, 1992	Van Scoik	424	469	
	5,178,878	Jan 12, 1993	Wehling et al.	424	466	
	5,273,975	Dec 28, 1993	Moon et al.	514	233.2	
	5,298,261	Mar 29, 1994	Pebley et al.	424	488	
	5,401,514	Mar 28, 1995	Juch et al.	424	465	
	5,417,985	May 23, 1995	Coutel et al.	424	489	
	5,431,918	Jul 11, 1995	Ferrero et al.	424	464	
	5,464,632	Nov 07, 1995	Cousin et al.	424	465	
	5,466,464	Nov 14, 1995	Masaki et al.	424	434	
	5,501,861	Mar 26, 1996	Makino et al.	424	464	
	5,503,846	Apr 02, 1996	Wehling et al.	424	466	
	5,518,730	May 21, 1996	Fuisz	424	426	
	5,562,917	Oct 08, 1996	Durif et al.	424	447	
	5,576,014	Nov 19, 1996	Mizumoto et al.	424	435	
	5,587,172	Dec 24, 1996	Cherukuri et al.	424	401	
	5,587,180	Dec 24, 1996	Allen, Jr. et al.	424	499	
	5,607,697	Mar 04, 1997	Alkire et al.	424	495	
	5,622,719	Apr 22, 1997	Myers et al.	424	488	
	5,624,677	Apr 29, 1997	EI-Rashidy et al.	424	435	
	5,653,926	Aug 05, 1997	Bogue et al.	264	120	
	5,662,849	Sep 02, 1997	Bogue et al.	264	112	
	5,733,577	Mar 31, 1998	Myers et al.	424	488	
	5,762,961	Jun 09, 1998	Roser et al.	424	464	
	5,770,606	Jun 23, 1998	EI-Rashidy et al.	514	284	
	5,807,576	Sep 15, 1998	Allen, Jr. et al.	424	465	
	5,837,285	Nov 17, 1998	Nakamichi et al.	424	464	

Examiner  Date Considered 4/15/05

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Rev. 8-88)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. C-3527/1/US	Serial No. 10/072,468
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Alice C. Martino et al.	AUG 14 2002 TECH CENTER 2000 USPTO ED
		Filing Date February 7, 2002	Group Unknown

## U.S. PATENT DOCUMENTS

Examiner Initial*		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
<i>SPH</i>							
		5,869,098	Feb 09, 1999	Misra <i>et al.</i>	424	484	
		5,876,759	Mar 02, 1999	Gowan, Jr.	424	494	
		5,888,534	Mar 30, 1999	El-Rashidy <i>et al.</i>	424	435	
		5,891,916	Apr 06, 1999	Kato <i>et al.</i>	514	575	
		5,939,091	Aug 17, 1999	Eoga <i>et al.</i>	424	441	
		5,939,094	Aug 17, 1999	Durif <i>et al.</i>	424	448	
		5,945,117	Aug 31, 1999	El-Rashidy, <i>et al.</i>	424	430	
		5,954,204	Sep 21, 1999	Grabowski	206	531	
		5,958,453	Sep 28, 1999	Ohno <i>et al.</i>	424	465	
		5,985,889	Nov 16, 1999	El-Rashidy <i>et al.</i>	514	284	
		5,994,363	Nov 30, 1999	El-Rashidy <i>et al.</i>	514	284	
		6,010,719	Jan 04, 2000	Remon <i>et al.</i>	424	464	
		6,024,981	Feb 15, 2000	Khankari <i>et al.</i>	424	464	
		6,083,527	Jul 04, 2000	Thistle	424	440	
		6,087,362	Jul 11, 2000	El-Rashidy	514	253	
		6,121,276	Sep 19, 2000	El-Rashidy <i>et al.</i>	514	284	
		6,193,992	Feb 27, 2001	El-Rashidy <i>et al.</i>	424	430	
		6,200,983	Mar 13, 2001	El-Rashidy <i>et al.</i>	514	284	
		6,291,471	Sep 18, 2001	Kling <i>et al.</i>	514	284	
<i>SPH</i>		6,306,437	Oct 23, 2001	El-Rashidy <i>et al.</i>	424	464	
		2002/0006933	Jan 17, 2002	Gupta <i>et al.</i>	514	295	

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
<i>SM</i>	EP0940084	Sep 08, 1999	EP	A23G	1/100		
	EP0960621	Dec 12, 1999	EP	A61K	31/505		
	EP0992240	Apr 04, 2000	EP	A61K	31/435		
	EP1145714	Oct 17, 2001	EP	A61K	31/4375		
	WO9916442	Apr 08, 1999	WIPO	A61K	31/47		
	WO9966933	Dec 29, 1999	WIPO	A61K	31/505		
	WO0035457	Jun 22, 2000	WIPO	A61K	31/485		
	WO0040226	Jul 13, 2000	WIPO	A61K	31/00		
<i>SM</i>	WO0042992	Jul 27, 2000	WIPO	A61K	9/70		
	WO0047203	Aug 17, 2000	WIPO	A61K	31/28		

**Examiner**

**Date Considered**

**\*Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449  
(Rev. 8-88)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.

Serial No.

C-3527/1/US

10/072,380

O / P E S T C R I T I C A L  
AUG 12 2002  
P A T E N T & T R A D E M A R K  
U S P S  
FORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Alice C. Martino et al.

Filing Date

February 7, 2002

Group No.

Unknown

TECH  
CENTER  
1600  
2900AUG  
14  
2002

RECEIVED

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
SJ	WO0076509	Dec 21, 2000	WIPO	A61K	31/44		
SJ	WO0110406	Feb 15, 2001	WIPO	A61K	9/00		
SJ	WO0149292	Jul 12, 2001	WIPO	A61K	31/485		
SJ	WO0176602	Oct 18, 2001	WIPO	A61K	31/473		
SJ	WO0205820	Jan 24, 2002	WIPO	A61K	31/495		

## OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

SJ	<a href="http://www.tomescps.com/hcsdata/de/de1066.htm">http://www.tomescps.com/hcsdata/de/de1066.htm</a> , pp. 1-33. Apomorphine
	Schuh et al. "Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet" <i>Drug and Alcohol Dependence</i> , 56(1), 55-60 (1999).
	Chang et al. "Fast-Dissolving Tablets", <i>Pharmaceutical Technology</i> , pp. 52-58, June (2000).
	Dong Yoo et al. "Increased Bioavailability of Clomipramine after Sublingual Administration in Rats", <i>Journal of Pharmaceutical Sciences</i> 88(11), (1999).
	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , 4 <sup>th</sup> edition (DSM-IV) (1994), and DSM-IV Guidebook (1995), both published by American Psychiatric Press, Inc., Washington, DC
	Gingell et al. "Emerging pharmaceutical therapies for erectile dysfunction", <i>Expert Opinion on Therapeutic Patents</i> 9, 1689-1696 (1999).
	Heier et al. "Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites", <i>J. Med. Chem.</i> 40,639-646, (1997).
	Shephard et al. "Pharmacokinetic behavior of sublingually administered 8-methoxysoralen for PUVA therapy", <i>Photodermatology, Photoimmunology &amp; Photomedicine</i> 17, 11-21(2001).
	Watson et al. "A Pharmacokinetic Study of Sublingual Aerosolized Morphine in Healthy Volunteers", <i>Journal of Pharmacy and Pharmacology</i> 48(12) (1996).
	<a href="http://www.tomescps.com/hscdata/de/de0598.htm">http://www.tomescps.com/hscdata/de/de0598.htm</a> , pp. 1-289. Nifedipine
	<a href="http://www.tomescps.com/hcsdata/de/de0035.htm">http://www.tomescps.com/hcsdata/de/de0035.htm</a> , pp. 1-163. Nitroglycerin
	<a href="http://www.ipet.aspjournals.org/cgi/content/full/296/1/121#sec3">http://www.ipet.aspjournals.org/cgi/content/full/296/1/121#sec3</a> . Scopolamine
	Mahmood, "Clinical Pharmacokinetics and Pharmacodynamics of Selegiline", <i>Clinical Pharmacokinetics</i> 33(2), 91-102 (1997).
	Deneer et al. "Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects", <i>British Journal of Clinical Pharmacology</i> 45(5), 485-490 (1998).
SJ	Russell et al. "Pharmacokinetics of a New Sublingual Formulation of Temazepam", <i>European Journal of Clinical Pharmacology</i> 35(4) (1988).

Examiner	Date Considered
<i>SJ</i>	<i>4/15/05</i>

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.